Sitemap - 2024 - The Microdose

What do we know about the psychedelic underground?: 5 Questions for drugs researcher Crystal Lederhos Smith

Preparing insurers and patients for MDMA-assisted therapy; NIH announces $20 million grant to study psychedelics and chronic pain; Are psychedelics an “inner healer”?

Psychedelics 101 for doctors: 5 Questions for Psychedelic Medicine Association founder Lynn Marie Morski

Federal agencies settle with ayahuasca church; U.S. reps urge VA to prepare for MDMA approval; CO bill could hamper psychedelics discussion on social media

Hasidic Judaism and Psychedelics: 5 Questions for Jewish studies scholar Sam Shonkoff

No serious adverse reactions recorded in synthetic 5-MeO-DMT study; California psychedelics bill advances; Are medical trainees ready for psychedelics?

Is it okay to give psychedelics to someone in a vegetative state?: 5 Questions for journalist Jonathan Moens

DEA announces hearing on obscure hallucinogenic compounds; Petitioning the FDA for a public meeting on Lykos and MDMA; Psychedelic church sues for defamation

Measuring the ineffable: 5 Questions for mystical experience researcher Kurt Stocker

Indigenous ketamine therapy: 5 Questions for First Nations mental health leader Emmy Manson

Tapering off antidepressants before psilocybin treatment; New concerns about MAPS’s MDMA trials; University of Maryland Baltimore joins patent lawsuit against Compass

Cognitive impairment, dementia, Alzheimer’s and psychedelics: 5 Questions for researcher Albert Garcia-Romeu

Another Breakthrough Therapy Designation for a psychedelic drug from the FDA; A critique of the mixing of psychedelic science and spirituality at Johns Hopkins; The patient-therapist bond

Cops for psychedelic reform: 5 Questions for retired police officer Dave Franco

“Hey, whatever happened to the tapes you made when I was high?”

MindMed receives FDA breakthrough therapy designation for LSD; Psychedelics figure Ben Sessa’s medical license suspended for one year; Serotonin toxicity after combining psilocybin and antidepressants

What is happening in Europe?: 5 Questions for Psychedelic Access and Research European Alliance founder Tadeusz Hawrot

Psilocybin-related calls to poison control centers increasing; former Kentucky ibogaine advocate to continue his work in Ohio; Colorado issues draft psilocybin rules

What happens when MDMA is approved as a prescription drug? 5 Questions for regulatory attorney Kimberly I. Chew

Psychedelic preparation going digital, more Canadian raids, and a new psilocybin services bill in Arizona

FDA will fast-track Lykos’s application for MDMA-assisted therapy for PTSD; New Illinois bill; and Canada’s first psilocybin clinical trial

Palliative care and psychedelics: 5 Questions for physician Rachel Rackow

Law enforcement seizures of psychedelic mushrooms skyrocket; Could psychedelics lead to better sex? And will CA be the next state to launch a psychedelics program?

What can Colorado learn from Oregon about psilocybin?: 5 Questions for Healing Advocacy Fund’s Colorado director Tasia Poinsatte

A cornucopia of new bills; Canadians support end-of-life psilocybin therapy; and tempering the hype

An undergrad, twitching rodent heads, DOI, and the DEA: 5 Questions for researcher Alyssa Gillies

Probing expectancy effects; EU to spend big on psilocybin trial; MDMA-assisted therapy may improve self-compassion

“Stop using wild San Pedro”: 5 Questions for Josip Orlovac Del Río

The long history of Psilocybe’s evolution; New bills in Indiana, California, and New Jersey; and COMPASS partners with a healthcare non-profit

Should Kentucky spend $42 million on ibogaine research? 5 Questions for drug abuse researcher William Stoops

Could ibogaine help treat brain injuries? MAPS rebrands its for-profit company; New year, new bills in AZ and RI

Drug use at the nightclub: 5 questions for drug epidemiologist Joseph Palamar

Kentucky ibogaine proposal in flux; A look at year one of psilocybin services in Oregon; Drug Enforcement Administration proposes to restrict two new drugs

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts